Because of abnormal activation of the mammalian target of rapamycin (mTOR) pathway in several neoplasms, including insulinoma, mTOR inhibitors have been increasingly recognized as a treatment option in patients with CHI (18,19). The gene discussed is MTOR; the disease is pancreatic insulinoma.